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Abstract
Malic enzyme 2 (ME2) is a mitochondrial enzyme that catalyzes the conversion of malate to pyruvate and CO2 and uses NAD
as a cofactor. Higher expression of this enzyme correlates with the degree of cell de-differentiation. We found that ME2 is
expressed in K562 erythroleukemia cells, in which a number of agents have been found to induce differentiation either
along the erythroid or the myeloid lineage. We found that knockdown of ME2 led to diminished proliferation of tumor cells
and increased apoptosis in vitro. These findings were accompanied by differentiation of K562 cells along the erythroid
lineage, as confirmed by staining for glycophorin A and hemoglobin production. ME2 knockdown also totally abolished
growth of K562 cells in nude mice. Increased ROS levels, likely reflecting increased mitochondrial production, and a
decreased NADPH/NADP
+ ratio were noted but use of a free radical scavenger to decrease inhibition of ROS levels did not
reverse the differentiation or apoptotic phenotype, suggesting that ROS production is not causally involved in the resultant
phenotype. As might be expected, depletion of ME2 induced an increase in the NAD
+/NADH ratio and ATP levels fell
significantly. Inhibition of the malate-aspartate shuttle was insufficient to induce K562 differentiation. We also examined
several intracellular signaling pathways and expression of transcription factors and intermediate filament proteins whose
expression is known to be modulated during erythroid differentiation in K562 cells. We found that silencing of ME2 leads to
phospho-ERK1/2 inhibition, phospho-AKT activation, increased GATA-1 expression and diminished vimentin expression.
Metabolomic analysis, conducted to gain insight into intermediary metabolic pathways that ME2 knockdown might affect,
showed that ME2 depletion resulted in high orotate levels, suggesting potential impairment of pyrimidine metabolism.
Collectively our data point to ME2 as a potentially novel metabolic target for leukemia therapy.
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Introduction
Malic enzymes (ME; EC 1.1.1.40) represent a family of
oxidative decarboxylases that catalyze the divalent metal ion
(Mn
2+ or Mg
2+) dependent irreversible oxidative decarboxylation
of L-malate to yield CO2 and pyruvate, with concomitant
reduction of dinucleotide cofactor NAD
+ or NADP
+ [1]. In
different species, these enzymes show highly conserved sequences
and similar overall structural topology, suggesting important
biological functions, which however are not well-defined. Three
isoforms of malic enzyme have been identified in mammals
according to their nucleotide specificity: cytosolic NADP
+-
dependent (ME1), mitochondrial NAD
+-dependent (ME2), and
mitochondrial NAD(P)
+-dependent malic enzyme (ME3). It has
been shown that ME2 favors NAD
+ as a cofactor under
physiological conditions, although it can use both NAD
+ and
NADP
+. ME2 is thought to be involved in the ultimate conversion
of malate to citrate, the latter being directed to the cytosol via the
carboxylate carrier [2]. Citrate that is extruded from mitochondria
is the primary precursor for the endogenous synthesis of fatty
acids, cholesterol, isoprenoid, as well as acetylation reactions that
modify proteins.
There is a paucity of information on the role of malic enzymes
in normal physiology and in disease states. It is important to
recognize that the literature is confusing in that sometimes the
malic enzyme is not specified (i.e. ME1 vs 2 vs 3) and in some
cases, the enzyme is confused with two of the malate dehydroge-
nases. Thus we cite here only references that provide the EC
number for ME2 or that clearly specify the activity in question as
being due to a mitochondrial NAD
+ dependent enzyme that
produces pyruvate from malate. Previous studies indicate that both
the cytosolic and mitochondrial malic enzyme are involved in
malate-pyruvate cycling under conditions of nutrient-stimuated
insulin secretion [3,4,5]. In neurons pyruvate produced from
malate is a substrate for the neuronal synthesis of c-aminobutyric
acid, found to be associated to idiopathic generalized epilepsy
through linkage analysis [6]. ME2 gene expression is 5.6-fold
lower in anterior cingulate tissue from post-mortem bipolar brains,
associated with both psychotic and manic disorders including
schizophrenia and bipolar disorders [6,7]. From a cancer
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12520standpoint, ME2 activity increases with progression to neoplasia in
a rat tracheal epithelial line [8] with similar findings in Morris
hepatomas [9]. Of interest, ME2 is present in tumor mitochondria
in levels proportional to the rate of cell division [9,10], while
curiously it is essentially absent in liver, regenerating liver, and the
mitochondria of other organs. ME2 interacts directly with the
malate-aspartate shuttle system. It is believed that ME2, via the
generation of NADH and pyruvate products, may play an
important role in the metabolism of glutamine, which is needed
to produce both reducing equivalents and energy in rapidly
proliferating tissues such as tumors. ME2 is regulated by ATP
which acts as an inhibitor and by fumarate which acts as an
activator of its catalytic activity [11,12,13]. This regulation is
consistent with the functional role of this enzyme, as ATP is an
overall product of energy metabolism and fumarate is generated
by the previous step in the TCA cycle. The possible functional
involvement of ME2 in neoplasia is strongly suggested by its
increased activity in tumor tissue. This finding implicates the
enzyme as a potentially attractive novel anti-cancer target and
warrants detailed investigation of its functional role in cancer.
The human K562 erythroleukemia cell line is a multipotent
hematopoietic precursor cell line derived from a patient with
chronic myeloid leukemia (CML) in blast crisis and thus provides a
model system to study gene expression during hematopoiesis.
These cells can be induced to differentiate along either the
erythroid or megakaryocytic lineages. A variety of chemical
compounds, such as hemin, butyrate, cisplatin, PMA, TPA, Ara-
C, the BCR-ABL signaling inhibitor imatinib, and the Hsp90
inhibitor radicicol have been found to induce K562 differentiation
[14,15]. Here we have used the K562 model system to study the
function of ME2 and find that silencing this gene leads to K562
cell apoptosis and erythroid differentiation and abolishes growth of
these cells in vivo.
Results
Knockdown of endogenous ME2 levels by shRNA impairs
proliferation of K562 cells
To investigate the effects of ME2 inhibition on K562 cells, we
produced recombinant lentiviral particles by expressing constructs
containing ME2 short hairpin RNAs (shRNA) and established
stable cell clones. Three independent constructs, shME2-1,
shME2-2, and shME2-3, were used to generate stable cell lines.
Each of these pools displayed significantly reduced ME2 protein
levels compared to control lentiviral vector only (pLKO) infected
cells (Figure 1A). These three pools were used in experiments
described in the Methods section to examine the role of ME2 in
K562 cell proliferation. As shown in Figure 1B, stable lentiviral
reduction of ME2 protein levels resulted in dramatic inhibition of
K562 cell growth in vitro. Furthermore, we established three single
clones from the three independent pools, designated as shME2-1s,
shME2-2s, and shME2-3s. The three single clones also displayed
marked reduction in ME2 protein levels (Figure 1C). As
anticipated, cell proliferation was markedly decreased in these
cells (Figure 1D).
Stable knockdown of endogenous ME2 levels by shRNA
induces erythroid differentiation in K562 cells
Next, we asked whether ME2 silencing would lead to
differentiation of K562 cells. We assayed for erythroid differen-
tiation by analyzing our pooled ME2 knockdown cells for
expression of glycophorin A (CD235a), a cell surface glycoprotein
Figure 1. Effects on K562 cell proliferation of three independent shRNA hairpins targeting ME2. A: Western blot analysis using an ME2
antibody of lysate from respective pools of cells transduced with three independent ME2 shRNA lentiviruses, and following selection of puromycin for
10 days as described under ‘‘Materials and Methods’’. Data are representative of two independent experiments. All three pools showed marked ME2
silencing. B: Cell proliferation in K562 cells transduced with the indicated shRNA lentiviral constructs as described in ‘‘A’’. Data are representative of
three independent experiments. C: Western blot analysis of cellular extracts in single clone K562 cells as described under ‘‘Materials and Methods’’
demonstrated effective knockdown of ME2 levels. Data are representative of two independent experiments. D: Cell proliferation of K562 single cell
clones with ME2 knockdown derived from the corresponding pools as described in ‘‘C’’. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0012520.g001
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cytes. Previously it has been shown that glycophorin A is induced
in K562 cells undergoing erythroid differentiation in response to
imatinib [16] or radicicol [15]. Compared to vector transduced
cells, ME2 knockdown cells displayed an increase in the surface
expression of this erythroid cell marker (Figure 2A). Similar results
were also obtained in single clones derived from shME2-2 and
shME2-3 pools (Figure 2B). Furthermore, quantitation of
hemoglobin-positive cells revealed that approximately 21.2%,
50.32%, and 31.52% of cells within the shME2-1, shME2-2 and
shME2-3 ME2 knockdown population, respectively, expressed
hemoglobin, compared to 4.4% for vector control infected K562
cells (Figure 2B and Figure S1).
K562 cells can also differentiate along the megakaryocytic
lineage. We assessed our ME2 knockdown cells for their degree
of megakaryocytic differentiation by analyzing the cells for
expression of CD10, a cell surface glycoprotein expressed
selectively on mature megakaryocytic cells that is induced in
K562 cells in response to PMA stimulation. As shown in
Figure 2C, there was no difference in expression CD10
between control and ME2 knockdown cells, suggesting that
deficiency of ME2 cells directs K562 cells toward erythroid
differentiation.
Knockdown of endogenous ME2 leads to apoptosis in
K562 cells and suppresses tumor growth in vivo
Tumor cell differentiation is often accompanied by increased
apoptosis [17]. Therefore, we examined apoptosis in K562 cells
with ME2 depletion by annexin-V/7-AAD staining. As shown in
Figure 3A, knockdown of ME2 levels caused a 2.8 to 3.3-fold
increase in basal apoptosis.
Next, we asked what the effects of ME2 depletion would be in
vivo by examining tumorigenicity of K562 cells in mice. We
injected vector control and ME knockdown clones (shME2-2 and
shME2-3) subcutaneously into nude mice and assessed tumor
formation and progression following injections. In one group of 4
mice, each mouse received a vector control inoculation in one
flank and an ME2 shRNA clone in the other, so that tumor
comparisons would be controlled for each individual mouse. In
another group of 2 mice, both of the flanks were injected with
another ME2 shRNA clone. Growth of tumors was monitored
weekly, and tumors were excised and weighed 6 to 8 weeks
Figure 2. Stable knockdown of endogenous ME2 levels in K562 cells induces erythroid differentiation. A: Expression levels of the
erythroid marker glycophorin A on the surface of control (pLKO) and ME2 knockdown cells (shME2-1, shME2-2 and shME2-3) were compared using a
mouse FITC-conjugated anti-human glycophorin A antibody. As a negative control (Neg Ctrl), cells were incubated with FITC-conjugated control IgG.
As a positive control, K562 cells were transduced with ATP citrate lyase (ACL) shRNA lentiviral particles (ACL inhibition is known to cause erythroid
differentiation in K562 cells – referenced in the text), and incubated with mouse FITC-conjugated anti-human glycophorin A antibody. The control
clone was generated by stable transduction of control pLKO vector, while clones shME2-1, shME2-2 and shME2-3 were generated using the pLKO-
ME2 shRNA lentivirus. Data are representative of three independent experiments. B: The percentage of hemoglobin-expressing cells in control (pLKO)
and ME2 knockdown (shME2-1, shME2-2 and shME2-3) cell populations was determined by benzedrine staining. Plotted is the mean 6 SD from
triplicate samples from a representative experiment. Insert: cell pellets from ME2 knockdown cells. 1: pLKO; 2: shME2-1; 3: shME2-2; 4: shME2-3.
Increased brown color is clearly visible in lanes 2, 3 and 4. C: Expression levels of the megakaryocytic marker CD10 on the surface of control (pLKO)
and ME2 knockdown cells (shME2-1, shME2-2 and shME2-3) were compared using a mouse FITC-conjugated anti-human CD10 antibody. As a
negative control (Neg Ctrl), cells were incubated with FITC-conjugated control IgG. The control clone was generated by stable transduction of control
pLKO vector, while clones shME2-1, shME2-2 and shME2-3 were generated using the pLKO-ME2 shRNA let virus. Data are representative of three
independent experiments.
doi:10.1371/journal.pone.0012520.g002
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tumors (Figure 3B).
Depletion of endogenous ME2 levels enhances reactive
oxygen species (ROS), increases NAD
+/NADH and
NADP
+/NADPH ratio and inhibits ATP production in K562
cells
The role of ROS in cell differentiation and cell survival is
complex. There is some evidence supporting the notion that
certain cancer cells are under increased oxidant stress. In
particular, increased ROS generation occurs in cancer cells
carrying mutations or activation of Ras, Bcr-Abl, and c-Myc
[18,19,20]. Further increases in ROS can promote differentiation
and additional increases can lead to apoptosis. Indeed, anticancer
drugs including doxorubicin, arsenic trioxide, and taxol have
been observed to generate ROS. Increasing ROS can induce
cell differentiation in K562 cells and in neuroblastoma cells
[21,22,23].
To determine if knockdown of ME2 promotes ROS production,
we first analyzed superoxide production in K562 cells with ME2
depletion by using the superoxide detection reagent MitoSOX
Red, a novel fluorogenic dye for highly selective detection of
superoxide in the mitochondria of live cells. This reagent is live-
cell permeant and is rapidly and selectively targeted to the
mitochondria. Once in the mitochondria, it is rapidly oxidized by
superoxide but not by other ROS- or reactive nitrogen species-
generating systems. We therefore stained ME2 knockdown K562
cells with MitoSOX Red, and observed the cells under
fluorescence microscopy. We only found positive cells in ME2
deficient K562 cells as compared to controls (Figure 4A). There
was a significant increase in MitoSOX red fluorescence in ME2
knockdown cells indicative of an increase in superoxide genera-
tion. The stability of superoxide is short-lived in cells, since
superoxide dismutase rapidly converts it into H2O2. Therefore, we
further assayed for H2O2 and other reactive species in response to
ME2 knockdown as quantified by flow cytometry using CD-
H2DCF-DA as a fluorescent probe. Compared to empty vector
control, we observed a significant increase in basal ROS content in
three independent ME2 shRNA knockdown cells (Figure 4B).
Furthermore, we detected oxidation of cardiolipin, a mitochon-
drial membrane lipid component by labeling with NAO. As shown
in Figure 4C, knockdown of ME2 caused massive cardiolipin
oxidation. About 31.28% and 23.19% of ME2 depleted cells
showed cardiolipin oxidation in two independent clones, respec-
tively (Figure 4C). Moreover, intracellular NADPH level has been
considered as an effective antioxidant. In agreement with the
increase of ROS in K562 cells, we found NADPH level decreased
in ME2 knockdown cells, a result that was confirmed using
metabolomic analysis described above (Figure 4F).
ME2 may play an important role in energy production fueled
by glutamine. Therefore, we examined ATP production in cells
with ME2 deficiency. As illustrated in Figure 4D, knockdown of
ME2 led to almost 50% ATP inhibition in three independent ME2
shRNA cells. Consistent with this observation, we noted a 2-fold
increase in the NAD
+/NADH ratio in ME2 knockdown cells
(Figure 4E).
Inhibition of ROS does not rescue ME2 deficiency
induced differentiation
ROS have been shown to induce K562 cell differentiation in
vitro [22]. We asked whether differentiation induced by knockdown
of ME2 occurs via increased ROS generation. To answer this
question, we inhibited ROS using NAC and examined differen-
tiation in K562 leukemia cells induced by ME2 depletion. 5.0 mM
NAC completely inhibited endogenous ROS in ME2 knockdown
leukemia cells (Figure 5A), without affecting differentiation
(Figure 5B), suggesting that ROS production is only a by-product
of ME2 knockdown.
The malate-aspartate shuttle (MAS) inhibitor
amino-oxyacetate (AOA) cannot induce K562
differentiation but induces cell death
One of the functions of ME2 is to generate NADH in the
mitochondria. We wondered if the ME2 knockdown phenotype
(K562 differentiation) might be due to decreased production of
mitochondrial NADH. Since the primary function of the MAS
shuttle is to transport malate into mitochondria and in so doing
essentially transfer cytosolic NADH equivalents into mitochondria
[24], we hypothesized that blockade of the MAS might cause
differentiation. To test this hypothesis, we used AOA, which when
added exogenously, is known to inhibit the aminotransferase in the
MAS. As illustrated in Fig. 6A, AOA from 0.2 to 0.8 mM in the
medium could not induce erythroid differentiation in K562 cells as
assessed by glycophorin staining.
Figure 3. Stable knockdown of endogenous ME2 levels in K562 cells results in apoptosis in vitro and suppresses tumor formation
from K562 cells in vivo. A: Knockdown of ME2 induces apoptosis in K562 as detected using the annexin V reagent. Data are expressed as mean 6
SD, n=3. B: Stable knockdown of ME2 in K562 cells failed to generate tumors in nude mice. Approximately 10
7 ME2 deficient or control K562 cells
resuspended in 200 ml of a serum-free culture medium/Matrigel mixture (1:1) were subcutaneously implanted into female athymic nude mice as
described under ‘‘Materials and Methods’’. Tumor-bearing mice were sacrificed after 4 weeks and the mice photographed before excision and
weighing. a, Left (L): pLKO; Right (R): shME2-2: b, L and R: shME2-3. Tumors formed only in the pLKO transduced cells.
doi:10.1371/journal.pone.0012520.g003
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depleted cells might lead to enhanced cell death, perhaps by
further decreases in mitochondrial NADH. Though no differen-
tiation was observed in AOA treated leukemia cells (Figure 6A),
the response of ME2 knockdown and control cells to AOA
treatment was quite dramatic. AOA induced leukemia cell death
(mainly apoptotic) when ME2 was silenced (Figure 6B, bottom). In
wild type K562 cells, AOA induced leukemia cell death (mainly
necrotic) (Figure 6B, top). Interestingly, a-ketoglutarate (a-KG)
could rescue AOA mediated cell death (Figure S2) suggesting that
the effect of AOA was likely due to blockade of glutamate to a-
KG, conversion, since AOA is known to be a nonspecific inhibitor
of pyridoxal phosphate-utilizing enzymes.
ME2 knockdown-induces K562 differentiation via the
PI3K/AKT pathway
A large body of evidence indicates that the erythroid
differentiation is accompanied by activation of the PI3K/AKT
pathway, while megakaryocytic differentiation is accompanied by
activation of the MAPK kinase pathway [25,26,27,28]. In the case
of erythroid differentiation, activation of PI3K/AKT is not merely
an association, since blockade of this pathway inhibits differenti-
ation [26,27,28].
We examined changes in these two pathways in ME2 depletion-
induced differentiation. Knockdown of ME2 using two indepen-
dent shRNAs resulted in a decrease in phospho-ERK levels
(Figure 7A). In contrast, the phospho-AKT308 and phospho-
AKT473 levels increased (Figure 7B). Furthermore, LY294002, a
PI3 kinase inhibitor, which has been shown to inhibit AKT
activity, rescues the differentiation mediated by ME2 silencing
(Figure 7C, D, and E). These data are consistent with the literature
[25,26,27]. GATA-1 is a transcription factor that is required and
sufficient to induce erythroid differentiation [29]. We observed a
GATA-1 increase in ME2 knockdown cells (Figure 7F). Vimentin
expression is diminshed during erythroid differentiation [30]. In
this study we found that vimentin was dramatically decreased in
ME2 depleted cells (Figure 7F). Our data suggest that the
differentiation induced by ME2 knockdown is most likely a
PI3K/AKT regulated event which also includes ERK repression,
Figure 4. Depletion of endogenous ME2 enhances ROS generation, increases NAD
+/NADH and NADP/NADPH ratios and decreases
ATP levels. A: Accumulation of mitochondrially generated superoxide in K562 ME2 knockdown cells as detected by MitoSOX. Data are
representative of two independent experiments. B: Increased ROS in K562 ME2 knockdown cells detected by flow cytometry using CM-H2DCF-DA.
Each histogram is representative of three experiments. C. Comparison of oxidative damage to cardiolipin in ME2 knockdown versus control K562
cells. M1 indicates subpopulation of cells that lost NAO signal due to cardiolipin oxidation. D. Depletion of ME2 inhibits ATP production in K562 cells.
Data are expressed as mean 6 SD, n=3. E: Depletion of ME2 increases NAD
+/NADH ratio. a, NAD
+ and NADH were measured by NAD/NADH Assay Kit
(Abcam, San Francisco, CA) as described in ‘‘Materials and Methods’’. Data are expressed as mean 6 SD, n=3. b, NAD+ and NADH were measured by
LC-MS methods as described in ‘‘Materials and Methods’’. F. Depletion of ME2 increases NADP/NADPH ratio in ME2 knockdown cells. NADP and
NADPH were measured by LC-MS methods as described in ‘‘Materials and Methods’’.
doi:10.1371/journal.pone.0012520.g004
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sion of vimentin.
Knockdown of endogenous ME2 levels impairs
pyrimidine metabolism in K562 cells
Several reports indicate that impairment of pyrimidine metabolism
induces leukemia cells differentiation [31]. Interestingly, in our
metabolomic analysis of ME2 knockdown cells we noted that there
was a marked increase in the metabolite orotate (approximately 90-
fold) in ME2 knockdown cells when compared to controls (Figure 8
and Table S1). Orotate is an intermediate in pyrimidine de novo
synthesis. Its accumulation in ME2 deficient K562 cells is suggestive
of a block in the synthesis or activity of UMP synthase. In support of
this hypothesis, we also found modest decreases in UMP, though we
are not ableto explain the lower levels of uridine, cytidine and inosine
(the latter involved in purinergic pathways) in ME2 knockdown cells
when compared with controls (Figure 8 and Table S1).
We might have expected that orotate accumulation would lead
to a block in DNA synthesis and S phase progression. However,
cell cycle analysis of ME2 knockdown cells did not indicate a block
in late G1 or early S phase (data not shown), nor were we able to
rescue the ME2 cell cycle phenotype (decreased proliferation) by
supplementation with uridine and cytidine (data not shown).
Discussion
We have provided the first evidence that the malic enzyme
family member ME2 is important in tumor biology; in particular,
in the differentiation program of K562 cells. A striking phenotype
that we observed upon ME2 knockdown, namely the induction of
erythroid differentiation and the inhibition of tumor growth, has
previously been observed by other manipulations that affect
metabolic pathways in K562 cells. For example, inhibition of
BCR-ABL signaling by treatment with imatinib in K562 cells [32]
would be expected to decrease glycolysis. K562 differentiation
along the erythroid lineage has also been noted after silencing of
ATP citrate lyase [33], a key enzyme in lipid synthesis. Another
study suggests that ME2 may play an important role in acute
lymphoblastic leukemia. French et al. [34] studied the genomic
determinants of methotrexate polyglutamates (MTXPGs) varia-
tion in acute lymphoblastic leukemia (ALL), and found that ME2
is among 7 genes which displayed all 3 types of genomic variation
associated with MTXPGs.
The mechanism by which depletion of ME2 causes tumor cell
differentiation remains to be elucidated. One possibility is that
malate accumulation plays a role, though our metabolite analysis
of whole cell extracts does not appear to support this, since malate
levels showed no change in total (mitochondrial plus cytosolic)
amount in ME2 knockdown cells as compared with control cells
(Table S1). It is conceivable though that mitochondrial malate
may be increased in the ME2 knockdown cells. Malate enters the
mitochondria from the cytosol (via the malate-aspartate shuttle)
[35]. Since the function of ME2 is to convert malate to pyruvate, it
is reasonable to assume that the accumulation of malate in
mitochondria may be playing a mechanistic role. Supplementation
of exogenous malate failed to induce K562 differentiation (data
not shown), suggesting that accumulation of this metabolite alone
cannot drive differentiation. However, we cannot rule this
possibility either, since malate sodium may not be able to get
into the cell and into mitochondria. Therefore, it is still possible
that mitochondrial malate accumulation explains some of the
ME2 knockdown phenotype.
A second possibility is that NADH depletion explains our
findings. Mitochondrial reducing equivalent shuttles are critical in
regulating the balance in NAD
+:NADH levels between the
cytoplasm and the mitochondria. The resultant effect of shuttle
activity is the net transfer of NADH across the inner mitochondria
membrane, in the production of ATP and the regeneration of
NAD
+ in the cytoplasm enabling further glucose metabolism and
lactate production. The increased drive to accumulate malate in
mitochondria due to ME2 silencing may prevent the transferring
of malate from cytosol to mitochondria, and render less effective
the function of the malate-aspartate shuttle from transferring
reduced equivalents from extra-mitochondrial to intra-mitochon-
drial compartments. Our metabolite data showing decreased
NADH/NAD
+ ratio in ME2 knockdown cells is consistent with
this view. Disruption of MAS has been reported to impair viability
and fetal growth in mouse blastocysts [36]. In our current
investigation we have shown that AOA, an MAS inhibitor, cannot
induce K562 differentiation. Instead, we found that AOA induces
cell death: apoptosis in ME2 knockdown cells and necrosis in the
control cells. The mechanism by which AOA plays different roles
in control and knockdown ME2 cells remains to be investigated: it
Figure 5. The antioxidant NAC cannot rescue ME2 knockdown
induced erythroid differentiation in K562 cells. A: 5 mM NAC
completely rescues ROS generation in K562 cells as detected by flow
cytometry using CM-H2DCF-DA. Each histogram is representative of
three experiments. B: ROS inhibition by 5.0 mM NAC did not rescue
ME2 knockdown induced erythroid differentiation in K562 cells. Each
histogram is representative of three experiments.
doi:10.1371/journal.pone.0012520.g005
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cause of cell death from AOA is likely due to inhibition of the
conversion of glutamate to a-KG, since a-KG rescued the cell
death effect.
A third possibility is that pyruvate depletion by ME2 silencing
plays a role; however, our metabolite data, given that it is whole
cell lysate data, does not definitively address this hypothesis.
We noted that the tumorigenic potential of ME2 deficiency
K562 cells in vivo was completely absent since injection of those
cells into nude mice failed to generate solid tumors. This is
intriguing in light of the fact the K562 cells that are fully
differentiated as a result of ME2 knockdown in vitro are still
growing albeit at a slower rate. It is possible that the knockdown of
ME2 indirectly disrupts additional unidentified pathways that are
of functional relevance in vivo e.g. critical for establishing tumor
take but not manifest in vitro.
Increased ROS generation is an important phenotype of highly
glycolytic cancer cells. ROS levels in cancer cells is also to be
regulated by the oncogenes such as Ras, Myc and Bcr-Abl
[18,19,20] and the tumor suppressor p53 [37]. Many anticancer
drugs enhance ROS production and thereby damage cell integrity.
However, the manipulation of cellular levels of ROS (smaller
increases in ROS than what are needed to cause cell death) can
induce cancer cell differentiation [17,21,22,23]. Our studies
indicate that silencing of ME2 in K562 cells is accompanied by
enhanced ROS generation and increased NAD
+/NADH and
NADP
+/NADPH ratios. Surprisingly, inhibition of ROS gener-
ation by treatment with the antioxidant N-acetyl-cysteine (NAC)
could not reverse this differentiation in ME2 knockdown cells,
demonstrating that although ROS is produced during K562
differentiation, ROS removal alone was insufficient to inhibit
differentiation of K562 cells. The decrease in ATP by about 50%,
perhaps due to decreased availability of NADH, may be a
contributing factor. In addition it is conceivable the reducing
power of NADH may lead to diminished capacity to maintain a
high enough ratio of NADPH/NADP
+, thus compromising,
reductive biosynthesis of fatty acids and cholesterol as well as
nucleic acid synthesis, needed to fuel cell proliferation. Indeed this
sequence of events may account for the increase in ROS that
results from depletion of ME2. Moreover, in K562 cells, depletion
of ME2 induced K562 erythroid differentiation is accompanied by
hemoglobin synthesis. Heme synthesis, which is localized to the
mitochondrial matrix, is accompanied by ROS production. In the
case of K562 cells, this may explain why we observed ROS levels
increasing in the ME2 knockdown cells [38].
There may also be a link between glutamine usage and ME2. In
order to obtain energy and the essential precursors for the
synthesis of macromolecules, tumor mitochondria adapt by
overexpressing glutaminase facilitating the use of glutamate as a
fuel. High levels of ME2 can then allow pyruvate to be produced
from malate within the mitochondria [2,9,39,40,41]. ME2 is one
of the few progression-linked enzymes in Morris hepatoma series
[9], as is a phosphate-dependent glutaminase [42], which strongly
suggests an important role of ME2 in glutamine metabolism in
tumors [2]. The oxidation of glutamate by tumor mitochondria is
accompanied by metabolic interactions with cytosolic malate and/
Figure 6. Supplementation by exogenous amino-oxyacetate in medium cannot induce erythroid differentiation but does induce
cell death. A. Cells were treated with different concentrations of amino-oxyacetate and expression levels of the erythroid marker glycophorin A on
the surface of K562 cells were assessed using a mouse FITC-conjugated anti-human glycophorin A antibody. Each histogram is representative of three
experiments. B. K562 cells with or without ME2 knockdown were incubated with different concentrations of AOA for 72 h. Cell death was assessed by
flow cytometry. Top: pLKO; Bottom: shME2-3. Data are representative of two independent experiments.
doi:10.1371/journal.pone.0012520.g006
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cytoplasm. These two major products play an important role in
tumor metabolism. Citrate is required for fatty acid and
cholesterol biosynthesis [43,44], the latter believed to be
characteristically enhanced in tumor cells [45]. Recently, Hatzi-
vassiliou and colleagues found that knockdown of ATP citrate
lyase (ACL) also induces K562 cell differentiation [33]. Acetyl-
CoA is an important component of fatty acid and cholesterol
biosynthesis in the cytosol, since it is the primary enzyme
responsible for the synthesis of cytosolic acetyl-CoA which is
important in lipid biosynthesis. Hence inhibition of ACL leads to
the disruption of lipid synthesis. These results suggest that
stimulating cytosolic acetyl-CoA production and lipid synthesis
may contribute to the suppression of tumor cell differentiation
[46]. Perturbation of the transition of TCA-to-lipid flux in the in
vivo tumor microenvironment may allow a tumor cell to initiate an
adaptive response such as differentiation in order to maintain its
survival. The upregulation of specific metabolic intermediates may
serve as signals to orchestrate these events. It is possible that citrate
may work as an import molecule in this molecular switch.
Therefore, disrupting citrate synthesis and transport to cytosol
could be an important therapeutic window for targeted tumor
therapy. The fact that ME2 selectively uses extra-mitochondria
malate to synthesize pyruvate and export citrate for lipid synthesis
[2] suggests that malic enzyme might be ideal for this type of
targeting. Our results indicated that depletion of ME2 suppresses
K562 proliferation and induces differentiation in a manner similar
to ACL knockdown. The differentiation induced by knockdown of
ME2 and ACL could therefore have a common mechanism,
namely inhibition of lipid synthesis. However, our metabolomic
Figure 7. Effects of ME2 knockdown on signaling pathways, and GATA-1 and vimentin expression. K562 cells with or without ME2
knockdown were lysed with RIPA lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% Triton X-100, 1 mM EGTA) containing 1 mM PMSF and a
protease inhibitor cocktail and subjected to centrifugation at 15,0006g for 10 min at 4uC to remove debris. After lysis, equal aliquots of protein lysate
were resolved by Western blotting. Western blots were probed with anti-phospho-ERK1/2, anti-ERK1, anti-p-AKT308, anti-AKT472, anti-AKT1/2, anti-
GATA-1, anti-vimentin and anti-b-tubulin. A, phospho-ERK1/2 activity in ME2 knockdown K562 cells. B, Phospho-AKT detection in ME2 knockdown
K562 cells. C, 10 mM PI3K inhibitor, LY294002, inhibits p-AKT activity. D, LY294002 rescue of differentiation in ME2 knockdown K562 cells. E, The effect
of LY294002 on the proliferation of K562 cells with or without ME2 knockdown. F, The expression difference of GATA-1 and vimentin in ME2
knockdown cells. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0012520.g007
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ME2 knockdown leads to diminished overall lipid synthesis though
we have not made a formal measurement of lipid flux. We did
observe significant shifts in lipid metabolism. Specifically, there
were increases in polyunsaturated free fatty acids and lipids that
contain polyunsaturated acyl groups, and decreases in lipids
containing saturated lipids. This effect may be driven by the high
levels of orotate in the knockdown cells and not directly by ME2
knockdown [47]. Orotate is an important precursor for pyrimidine
de novo synthesis. The accumulation of orotate in ME2 depletion
cells suggests that pyrimidine metabolism may be blocked. Some
data suggests that inhibition of early de novo purine biosynthesis,
or specific inhibition of de novo guanine nucleotide biosynthesis,
may be an obligatory step in the initiation of differentiation in
HL60 and K562 cells [48,49] induced by certain drugs . Our data
suggests that pyrimdine synthesis may be affected, although we
were unable to demonstrate the G1/S arrest phenotype that might
be expected if this were the mechanism involved in decreased cell
proliferation observed in ME2 knockdown cells. Our data indicate
that although the ME2 knockdown slowed cell growth, the cells
did not accumulate in any one position in the cell cycle and in fact,
supplementation with cytidine or uridine could not rescue the
differentiation mediated by ME2 depletion (data not shown). Also,
the reason why depletion of ME2 leads to the accumulation of
orotate is not known, though one target may be the activity or
expression of UMP synthase.
Does ME2 depletion affect other cancer cell types? We have
found marked effects in several tumor types in vitro and in vivo: in
MCF7 breast cancer cells and A549 non-small cell lung cancer
cells, ME2 silencing leads to differentiation and to increased
apoptosis (data not shown).
K562 cells behave as pluripotent hematopoietic precursor cells
[50,51]. Studies have shown that drugs such as imatinib, butyrate,
SB202190, hemin, hydroxyurea and Ara-C induce erythroid
differentiation [52,53,54,55,56,57], whereas phorbol esters such as
PMA induce megakaryocytic differentiation [52]. Both differen-
tiation pathways are driven by the activation of different signal
transduction pathways. For megakaryocytic differentiation, cells
require the activation of the ERK signaling pathway and the
inhibition of p38 MAP kinase [58]. For erythroid differentiation,
ERK1/2 signaling inhibition and AKT signaling pathway and
GATA-1 transcription factor activation are necessary [55]. In our
studies we found ERK1/2 signaling to be inhibited, while AKT
signaling was activated in ME2 knockdown K562 cells, consistent
with our observed phenotype of erythroid differentiation. At what
point in the signaling cascades ME2 knockdown has its effects is
under investigation.
In conclusion our data indicate that ME2 plays a crucial role in
modulating K562 cell differentiation and growth and highlight a




Dichlorodihydrofluorescein diacetate (CM-H2DCF-DA), Mito-
SOX
TM, and nonyl acridine orange (NAO) were purchased from
Invitrogen/Molecular Probes (Carlsbad, CA). Lipofectamine 2000
and tissue culture reagents were purchased from Invitrogen. The
pLKO constructs containing short hairpins RNAi (shRNA)
targeted to ME2 and ATP citrate lyase (ACL), and its control
vector were purchased from OPEN biosystems. All restriction
enzymes were obtained from New England Biolabs. The QIAprep
kit was from QIAGEN. Fetal bovine serum (FBS) was obtained
from GIBCO. Puromycin, anti-ME2 polyclonal antibody and
anti-b-tubulin monoclonal antibody were purchased from Sigma.
The anti-vimentin monoclonal antibody was from Santa Cruz
Biotechnology. The anti-GATA-1, phospho-ERK1/2, phospho-
AKT308, phospho-AKT473 and AKT1/2 polyclonal antibodies
were purchased from Cell Signaling Technology. The ERK1/2
moloclonal antibody was from Zymed. The CD235a-FITC and
CD10-FITC monoclonal antibodies were obtained from DAKO.
Secondary antibodies for enhanced chemiluminescence (ECL)
detection were from Amersham Biosciences. All other reagents
were of standard analytical grade.
Cell Culture
The human erythroleukemia K562 cell line was obtained from
American Type Culture Collection and grown in Iscove’s
Modified Medium. All media were supplemented with 10% (v/
v) fetal calf serum, 100 units penicillin and 100 mg/ml streptomy-
cin, and grown at 37uC and 5% CO2. Cells infected with shRNA
virus were selected with 1.0 mg/ml puromycin and stable knock-
down of ME2 or ACL were used for analysis.
Generation of ME2 deficiency cell lines
K562 cells were transduced separately with empty shRNA
vector control, three different ME2 and one ACL shRNA
lentiviral particles as previously described [59]. ATP citrate lyase
(ACL) shRNA lentiviral knockdown cells were used as a positive
controls. The three ME2 shRNA sequence (sense) used in this
study are: shME2-1, 59-CGGCATATTAGTGACAGTGTT-39;
shME2-2, 59-CCCAGTATGGACACATCTTT A-39; and
shME2-3, 59-GCACGGCTGAAGAA GCATAT A-39. The
shACL sequence is: 59-GCCTCTTCAATTTCTACGAG-
GACTT-39. To produce recombinant lentiviral particles, subcon-
fluent 293FT cells were cotransfected with 3 mg of a shRNA
plasmid, and 9 mg virapower packaging mix (Invitrogen) using
lipofectamine 2000 (Invitrogen). After 16 h culture medium was
switched to regular growth medium and cells were allowed to
incubate for additional 48 hours. Conditioned cell culture media
containing recombinant lentiviral particles were harvested and
frozen. K562 cells were transduced with above cell culture
supernatant containing lentiviral particles for 24 hours. These cells
Figure 8. Knockdown of ME2 alters pyrimidine metabolism in
K562 cells. The metabolites were measured by LC-MS method as
described in ‘‘Materials and Methods’’.
doi:10.1371/journal.pone.0012520.g008
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cell lines encoding empty vector shRNA, ME2 shRNA or ACL
shRNA. Hereafter, we named those pools pLKO, shME2-1,
shME2-2, shME2-3 and shACL, respectively. In order to generate
single ME2 knockdown clone, cells from the stable knockdown
pools were serially diluted in 96-well plates. The single clone
corresponding to its parental pools were named pLKO-s, shME2-
1s, shME2-2s and shME2-3s, respectively.
Western Blotting
K562 cells with and without ME2 knockdown treated with
10 mM LY294002 or DMSO were lysed with RIPA buffer
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% SDS
and 0.5% sodium deoxycholate), and equal amount of proteins
were resolved by 4%–12% Bis-Tris gels (Invitrogen), as previously
described [60]. Briefly, the proteins were transferred to a PVDF
membrane, and membranes were blocked with BLOTTO (5%
nonfat dry milk and 0.1% Tween 20 in PBS), and incubated with
antisera generated against ME2, phospho-AKT380, phosphor-
473, AKT1/2, phosphor-ERK1/2, ERK1, Vimentin, GATA-1 or
b-tubulin antibodies respectively. Membranes were washed in PBS
plus 0.1% Tween 20 and probed with anti-rabbit or anti-mouse
HRP-conjugated secondary antibody (both at 1:10,000 dilution),
and proteins were detected using the ECL Plus chemilumines-
cence detection reagent (Amersham Biosciences).
Proliferation assay
Control and ME2 deficient cell lines were plated in 6-well plate
at a density of 1610
5 cells/well and maintained at 37uCi na5 %
CO2 incubator. After 24, 72, 120 and 168 hours of initial plating,
0.5 ml cells were diluted into 10 ml of Hanks’ buffer and counted
by Coulter counter. All samples were assayed in triplicate to
generate proliferation curves as described [61].
Erythroid differentiation assay
Induction of surface expression of the erythroid marker
glycophorin A and CD10 was determined by indirect immuno-
fluorescence and flow cytometry as described previously by
Hatzivassiliou and colleagues [33]. In brief, K562 cells with or
without ME2 knockdown were stained with a mouse FITC-
conjugated anti-glycophorin A or CD10 antibody (Dako) at 1:100
dilution in medium plus 10% FCS for 30 min at 4uC. Control,
cells were stained with FITC-conjugated IgG. Cells expressing
hemoglobin were determined by benzidine staining as previously
described by Park and colleagues [62]. The benzidine dihydro-
chloride stock solution contained 0.2% w/v benzidine hydrochlo-
ride in 3% acetic acid. Cells (1610
5) were washed twice in ice-cold
PBS. The cell pellets were resuspended in ice-clod PBS. Before
staining, 5 ml of 30% H202 was added to 1 ml of a stock solution of
benzidine solution. The cell suspensions were mixed with the
benzidine solution in a 1:1 ratio and counted in a hemocytometer
after 30 min. Blue cells were considered to be positive for
hemoglobin. The proportion of blue-stained cells was quantified
under light microscopy. A total of 500 cells were counted for each
sample in triplicate. Shown is the mean 6 SD of a representative
experiment.
Annexin-V apoptosis assay
Apoptosis was measured by staining with the Nexin reagent
using a Nexin kit and counting on the Guava PCA-96 system
(Guava Technologies) as per the manufacture’s protocol. Briefly,
cells were harvested and re-suspended in 100 ml of 1X Nexin
buffer, and then mixed with 100 ml of Annexin-V-PE, and Nexin
7-AAD. The cells were allowed to incubate for 20 minutes at room
temperature and analyzed in the Guava flowcytometer.
Determination of cellular reactive oxygen species (ROS)
Intrcellular ROS production was measured by staining with CM-
H2DCFDA. CM-H2DCFDA is a cell-permeant indicator for ROS
that is nonfluorescent until removal of the acetate groups by
intracellular esterases and oxidation occurs within the cell. The
procedure for measuring ROS was carried out as described earlier,
with minor modification [63]. Briefly, K562 cells transduced with
shRNA lentiviral particles or control vector were selected with
puromicin for 2 weeks, and then incubated with 5 mM CM-H2DCF-
DA for 3 hours, followed by flow cytometry using a FACSCalibur
equipped with CellQuest Pro software. Superoxide radicals (O2
2)
were measured separately using the MitoSOX reagent according to
the manufacturer’s protocol (Invitrogen). In brief, cells with or
without ME2 knockdown were incubated with 5 mMM i t o S O X
TM
r e a g e n tf o r1 0m i n u t e sa t3 7 uC, then washed three times and
observed under a fluorescence microscope using the Rhodamine filter
and Axiovision software for capturing images (Zeiss, Germany).
Determination of oxidative damage to mitochondrial
membranes
Mitochondrial membrane lipid peroxidation was detected as
described [63]. K562 cells transduced with shRNA lentiviral
particles or control vector were selected with puromycin for 2
weeks, and then labeled with 50 nM NAO for 20 min and
analyzed by flow cytometry using FL2 or 3 filters and Cell Quest
software analysis data (Becton Dickson).
Xenograft model in nude mice
Animal experiments were performed under federal guidelines
and approved by the Institutional Animal Care and Use
Committee (IACUC) of the Beth Israel Deaconess Medical Center
(Approval number 0342007). K562 xenografts in nude mice were
generated by following the description of Verrax J et al. [64].
Briefly, approximately 10
7 ME2 deficient or control K562 cells
resuspended in 200 ml of a serum-free culture medium/Matrigel
mixture (1:1) were subcutaneously injected into the right and left
flanks of male nude/nu/nu athymic mice, respectively. Tumor-
bearing mice were sacrificed after 6–8 weeks and tumor masses
were measured or imaged before excision. Tumor lysates were
prepared by homogenization of tumor tissues in RIPA lysis buffer
and were resolved by SDS-PAGE and transferred onto PDVF
membranes and immunoblotted with anti-ME2 antibody and
normalized by b-tubulin as a loading control.
Intracellular ATP measurements
Intracellular ATP levels in control and ME2 deficient cells were
measured by ATP Bioluminescence Assay Kit CLS II (Roche,
Germany) according to manufacturer’s instructions. Briefly, cells
were diluted to a concentration of 10
7 cells/ml, then add 9
volumes of boiling lysis buffer (100 mM Tris, 4 mM EDTA,
pH 7.75) and incubated for another 2 minutes at 100uC. Cell
lysates were collected by centrifugation and pelleting at 10006g
for 1 min, and 50 ml of samples were transferred into a MTP-well,
and mixed with 50 ml luciferase reagent. Luminescence was
measured using a luminescence reader (Molecular Devices), and




+ and NADH levels in control and ME2
deficient cells were measured by NAD
+/NADH Assay Kit
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instructions. Briefly, 2610
5 cells were washed with cold PBS and
extacted with NADH/NAD Extraction Buffer by freeze/thaw two
cycles (20 min on dry-ice, then 10 min at room temperature).
Total NADt and NADH were detected following the instruction in
a 96-well plate and color were developed and read at 450 nm. The
concentration of NADt or NADH was expressed in pmol/10
6
cells. NAD/NADH Ratio is calculated as: [NADt – NADH]/
NADH.
Metabolite profiling
To determine differences in metabolite profiles between ME2-
depleted and control cells, metabolite extracts were prepared and
then analyzed using liquid chromatography tandem mass
spectrometry (LC-MS). Briefly, K562 cells with or without ME2
depletion were washed once and resuspended in fresh growth
medium and grown an additional 2–4 h. To initiate the
extractions, cells were spun down and media were vacuum
aspirated. Lipids were extracted with the addition of 4 mL
isopropanol (4uC) and polar metabolites were extracted with the
addition of 4 mL 80% methanol (280uC). Following the addition
of extraction solvent, the samples were vortexed for 1 minute, held
for 1 h (4uC for lipid extracts; 280uC for polar metabolite
extracts), and then centrifuged at 3500 rpm for 10 minutes. The
supernatants were transferred to new tubes. For polar metabolites,
the pellet was resuspended in 1 ml 80% methanol (280uC),
vortexed for another 1 min, centrifuged as described above, and
the supernatants were combined.
LC-MS data were acquired using 4000 QTRAP triple
quadrupole mass spectrometers (Applied Biosystems/Sciex, Foster
City, CA) equipped with HTS PAL autosamplers (Leap
Technologies, Carrboro, NC) and either Agilent 1100 Series or
Agilent 1200 Series binary HPLC pumps (Santa Clara, CA).
Several chromatographic methods were used to profile endoge-
nous metabolites. Lipids were analyzed using a ProSphere C4
HPLC column (15063 mm; Grace, Columbia, MD) and full scan
MS data were acquired in the positive ion mode. Biogenic amines
and other positively charged polar metabolites were separated
using an Atlantis HILIC column (15062.1 mm; Waters, Milford,
MA) that was eluted with a 10 min linear gradient, initiated with
100% mobile phase B (acetonitrile with 0.1% formic acid, v/v)
and concluding with 60% mobile phase A (10 mM ammonium
formate and 0.1% formic acid, v/v). Central metabolites,
pyrimidines, and other negatively charged polar compounds were
analyzed using the ion paring chromatography method described
by Lou et al. with minor modification to the gradient program
[65]. Mobile phases used in the modified method were 10 mM
tributylamine/15 mM acetic acid (mobile phase A) and methanol
(mobile phase B) and the column was eluted at a flow rate of
200 ml/min using the following program: 100% mobile phase A at
initiation, 100% A at 4.5 min, 80% A at 7.5 min, 70% mobile
phase A at 26.5 min, 2% mobile phase A at 36.5 min, and 2%
mobile phase A at 40.5 min. Multiple reaction monitoring (MRM)
was used to acquire targeted MS data for specific metabolites in
the in the positive (HILIC method) and negative ion (ion paring
method) modes. Declustering potentials and collision energies
were optimized for each metabolite by infusion of reference
standards prior to sample analyses. The scheduled MRM
algorithm in the Analyst 1.5 software (AB SCIEX; Foster City,
CA) was used to automatically set dwell times for each transition.
MultiQuant software (Version 1.1; AB SCIEX; Foster City, CA)
was used for automated peak integration and metabolite peaks
were manually reviewed for quality of integration and compared
against a known standard to confirm identity.
Supporting Information
Figure S1 Stable knockdown of endogenous ME2 levels in K562
cells induces erythroid differentiation. The percentage of hemo-
globin-expressing cells in control (pLKO) and ME2 knockdown
(shME2-1, shME2-2 and shME2-3) cell populations was deter-
mined by benzedrine staining. Plotted is the mean 6 SD from
triplicate samples from a representative experiment.
Found at: doi:10.1371/journal.pone.0012520.s001 (0.12 MB TIF)
Figure S2 The effect of a-ketoglutarate (a-KG) on AOA-
induced K562 cell death. K562 cells with or without ME2
knockdown were incubated with 0.1 mM AOA plus 2 mM a-KG
for 48 h. Cell death was assessed by flow cytometry. A. pLKO
K562 cells without any treatment. B. pLKO K562 cells treated
with 0.1 mM AOA for 48 h. C. pLKO K562 cells treated with
0.1 mM AOA combined with 2 mM a-KG. Data are represen-
tative of two independent experiments.
Found at: doi:10.1371/journal.pone.0012520.s002 (0.32 MB TIF)
Table S1 Metabolite levels in lysates from control K562 (pLKO)
and ME2 knockdown (shME2-3) cells. The metabolites were
measured by LC-MS method as described in ‘‘Materials and
Methods’’.
Found at: doi:10.1371/journal.pone.0012520.s003 (0.05 MB
XLS)
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